Tagmokitug not checked

Coherus Oncology, Inc. · CHS-114

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
3 active
3 in total
Targets
 

What this is

How it works
An antibody: a lab-made immune protein built to latch onto one target in the body.-tug: unmodified immunoglobulins WHO name stem
Tested for
Advanced Solid Tumor (2 trials), Solid Tumor, Head and Neck Squamous Cell Carcinoma, Metastatic Solid Tumor
Main trialPhase 1/2
“The primary purpose of this study is to evaluate the safety and tolerability of tagmokitug in combination with other therapies.”In the company’s words, NCT07945821 on ClinicalTrials.gov
Other names
CHS-114

Other drugs for Advanced Solid Tumor

All 2440 drugs for Advanced Solid Tumor

Coming up2

Changes1

Last 90 days

Trials3

TrialPhaseCompletesWhat it tests
Phase 1/2Recruiting Aug 2028 A Study of Tagmokitug in Combination With Other Treatments in Participants With Advanced or Metastatic Solid Tumors
Phase 1Active, not recruiting 30 Sep 2026 Study of CHS-114 in Participants With Advanced Solid Tumors
Phase 1Recruiting Jan 2028 A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Tagmokitug

Following is part of Solo: you see every change to Tagmokitug the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in